UNSPSC 51313308: Thiazinamium metilsulfate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H23N2S.CH3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IA16WBX317, chemically known as 10h-phenothiazine-10-ethanaminium, n,n,n,alpha-tetramethyl-, methyl sulfate but more generally known as thiazinamium methylsulfate, which bears US NIH Compound Identifier 6015. European Medicines Agency schedules Thiazinamium metilsulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10971MIG.

UNSPSC 51313308 Thiazinamium metilsulfate is a Commodity code under which state and local governments procure pharmaceutical products, though the recent solicitations tagged under this code diverge significantly from the specific chemical compound the code nominally describes. The scope of work actually being solicited spans generic multi-source pharmaceuticals, over-the-counter products, naloxone, and drug deactivation systems through county health departments, state health and human services agencies, and multistate cooperative purchasing vehicles. Issuing bodies include county governments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local facilities across multiple states including Minnesota and Oregon). These entities typically require vendors to supply products through authorized wholesalers, maintain current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, provide National Drug Codes and detailed product information, and demonstrate pricing flexibility across multiple formats.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a response deadline of July 26, 2023 (note: the due date predates the posting date, indicating a data integrity issue in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract performance beginning July 1, 2026; this vehicle serves multiple participating jurisdictions and establishes pricing weighted 75 percent on competitiveness and requires vendors to maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC.